Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 17409425
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BRAF somatic mutations in malignant melanoma and melanocytic naevi

  2006cited by this paper
• HIFing the Brakes: Therapeutic Opportunities for Treatment of Human Malignancies

  2006cited by this paper
• Modelling cancer in human skin tissue

  2006cited by this paper
• Therapeutic targets in melanoma: MAPKinase pathway

  2006cited by this paper
• Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells

  2006cited by this paper
• B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.

  2006cited by this paper
• Essential role of B-Raf in ERK activation during extraembryonic development

  2006cited by this paper
• Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

  2006cited by this paper
• Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.

  2006cited by this paper
• Functional erythropoietin autocrine loop in melanoma.

  2005cited by this paper
• Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

  2005cited by this paper
• Roles of RAS and BRAF mutations in thyroid carcinogenesis.

  2005cited by this paper
• HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression.

  2005cited by this paper
• The Spitz nevus is melanoma.

  2005cited by this paper
• In vitro study of HIF‐1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI‐3K/Akt and MEK1/ERK pathways

  2005cited by this paper
• Update on angiogenesis inhibitors.

  2005cited by this paper
• Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Ras-dependent induction of HIF-1α785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion

  2004cited by this paper
• Novel Function of Orphan Nuclear Receptor Nur77 in Stabilizing Hypoxia-inducible Factor-1α*

  2004cited by this paper
• Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma.

  2004cited by this paper
• Hypoxia inducible factor-1alpha as a cancer drug target.

  2004cited by this paper
• Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.

  2003cited by this paper
• Molecular responses to hypoxia in tumor cells

  2003cited by this paper
• Suppression of BRAF(V599E) in human melanoma abrogates transformation.

  2003cited by this paper
• Raf proteins and cancer: B-Raf is identified as a mutational target.

  2003cited by this paper
• BAY-43-9006 Bayer/Onyx.

  2003cited by this paper
• The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.

  2003cited by this paper
• Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Oxygen-sensitive pro-inflammatory cytokines, apoptosis signaling and redox-responsive transcription factors in development and pathophysiology.

  2002cited by this paper
• Oxygen homeostasis and cancer: insights from a rare disease.

  2002cited by this paper
• The Raf/MEK/ERK pathway: new concepts of activation

  2001cited by this paper
• Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein

  2000cited by this paper
• Isotype-specific functions of Raf kinases.

  1999cited by this paper
• HIF-1 alpha is required for solid tumor formation and embryonic vascularization.

  1998cited by this paper
• Endothelial apoptosis in Braf-deficient mice

  1997cited by this paper
• Purification and Characterization of Hypoxia-inducible Factor 1 (*)

  1995cited by this paper
• MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity.

  1994cited by this paper
• Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

  1992cited by this paper

• Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma

  2025cites this paper
• MRS and Optical Imaging Studies of Therapeutic Response to Combination Therapy Targeting BRAF/MEK in Murine Melanomas.

  2025cites this paper
• Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer types

  2025cites this paper
• Unraveling the role of hypoxia-inducible factors in cutaneous melanoma: from mechanisms to therapeutic opportunities

  2025cites this paper
• Impact of trehalose and hydroxychloroquine on the function of BRAF (V600E)-siRNA in the A375 melanoma cells

  2025cites this paper
• Metabolic Reprogramming in Melanoma: An Epigenetic Point of View

  2025cites this paper
• BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome

  2025cites this paper
• Case report: a rare case of diffusely metastatic BRAF V600E-mutated colorectal cancer with concomitant infiltration of the skin and parotid gland

  2025cites this paper
• Extracellular vesicle-mediated gene therapy targets BRAFV600E-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathway

  2025cites this paper
• Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity

  2024cites this paper
• Metabolic insights into tumor lymph node metastasis in melanoma

  2024cites this paper
• Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials

  2024cites this paper
• Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review.

  2024cites this paper
• Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma

  2024cites this paper
• Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications

  2023cites this paper
• Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype

  2023cites this paper
• The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer

  2023cites this paper
• In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes

  2023cites this paper
• WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma

  2022cites this paper
• Status of BRAF in Odontogenic Keratocysts

  2022cites this paper
• NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets

  2022cites this paper
• HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia

  2022cites this paper
• Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study

  2021cites this paper
• Canonical Signaling Pathways in Melanoma.

  2021cites this paper
• Mitochondrial Metabolism in Melanoma

  2021cites this paper
• Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts

  2021cites this paper
• Specific Inhibition of HIF Activity: Can Peptides Lead the Way?

  2021cites this paper
• Biophysical characterization of melanoma cell phenotype markers during metastatic progression

  2021cites this paper
• Hypoxia-dependent drivers of melanoma progression

  2021cites this paper
• TGPred: a tumor gene prediction webserver for analyzing structural and functional impacts of variants

  2020cites this paper
• Hypoxia and Macrophages Act in Concert Towards a Beneficial Outcome in Colon Cancer

  2020cites this paper
• A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma

  2020cites this paper
• Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT).

  2020cites this paper
• The Complex Role of Autophagy in Melanoma Evolution: New Perspectives From Mouse Models

  2020cites this paper
• Xanthomicrol Exerts Antiangiogenic and Antitumor Effects in a Mouse Melanoma (B16F10) Allograft Model

  2020cites this paper
• Identification of Signatures of Prognosis Prediction for Melanoma Using a Hypoxia Score

  2020cites this paper
• Hif-1α Inhibitors Could Successfully Inhibit the Progression of Differentiated Thyroid Cancer in Vitro

  2020cites this paper
• Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment

  2020cites this paper
• Melanoma Metabolism: Cell Survival and Resistance to Therapy.

  2020cites this paper
• CXCR7 promotes melanoma tumorigenesis via Src kinase signaling

  2019cites this paper
• Characterization of glycolysis-related gene expression in malignant melanoma.

  2019cites this paper
• A New Classification Method of Metastatic Cancers Using a 1H-NMR-Based Approach: A Study Case of Melanoma, Breast, and Prostate Cancer Cell Lines

  2019cites this paper
• Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro

  2019influential citation
• MAPK SIGNALLING PATHWAY: ROLE IN CANCER PATHOGENESIS

  2019cites this paper
• Mitochondrial metabolism is inhibited by the HIF1α‐MYC‐PGC‐1β axis in BRAF V600E thyroid cancer

  2019cites this paper
• Mitochondrial metabolism is inhibited by the HIF1 a -MYC-PGC-1 b axis in BRAF V600E thyroid cancer

  2019cites this paper
• Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors.

  2018cites this paper
• HIF 1 a and HIF 2 a independently activate SRC to promote melanoma metastases

  2018cites this paper
• Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis

  2018cites this paper
• Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications

  2018influential citation
• RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma.

  2018cites this paper
• Employing the enzyme cofactor function of ascorbic acid to affect oncogenic pathways in human melanoma: modulating Hypoxia Inducible Factor-1α and DNA demethylation to reduce malignant potential

  2017cites this paper
• Melanoma topology reveals a stem-like phenotype that promotes angiogenesis

  2017cites this paper
• Overcoming resistance to BRAF inhibitors.

  2017influential citation
• Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach

  2017cites this paper
• Ascorbic acid, but not dehydroascorbic acid increases intracellular vitamin C content to decrease Hypoxia Inducible Factor -1 alpha activity and reduce malignant potential in human melanoma.

  2017cites this paper
• Hypoxia‐induced HIF1α targets in melanocytes reveal a molecular profile associated with poor melanoma prognosis

  2017cites this paper
• The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4

  2016cites this paper
• Acidic tumor microenvironment in human melanoma

  2016cites this paper
• Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors.

  2016cites this paper
• DCA as a possible therapy for cutaneous melanome in combination with approved therapeutics

  2016cites this paper
• Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib.

  2016cites this paper
• HIF-1α expression and high microvessel density are characteristic features in serrated colorectal cancer

  2016cites this paper
• The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer

  2016cites this paper
• The role of the membrane scaffolding protein KAI1 in human cutaneous melanoma

  2016cites this paper
• Hypoxia induces copper stable isotope fractionation in hepatocellular carcinoma, in a HIF-independent manner.

  2016cites this paper
• The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane

  2016cites this paper
• Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.

  2015cites this paper
• Diminution of miR-340-5p levels is responsible for increased expression of ABCB5 in melanoma cells under oxygen-deprived conditions.

  2015cites this paper
• The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth

  2015cites this paper
• Hypoxia-Independent Drivers of Melanoma Angiogenesis

  2015cites this paper
• Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia

  2015cites this paper
• The potential role of HIF on tumour progression and dissemination

  2015cites this paper
• Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy

  2015cites this paper
• Molecular drivers of cellular metabolic reprogramming in melanoma.

  2015cites this paper
• Metabolic features of melanoma: a gold mine of new therapeutic targets?

  2014cites this paper
• Exploitation du métabolisme mitochondrial oxydatif dans l'éradication du mélanome métastatique

  2014cites this paper
• MAP kinase activity supported by BRAFV600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases

  2014influential citation
• PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms

  2014cites this paper
• Human skin neural crest progenitor cells are susceptible to BRAFV600E-induced transformation

  2014cites this paper
• Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

  2014cites this paper
• Expression pattern of carbonic anhydrase IX in Medullary thyroid carcinoma supports a role for RET-mediated activation of the HIF pathway.

  2014cites this paper
• The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression

  2013cites this paper
• Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells

  2013cites this paper
• Putative role of HIF transcriptional activity in melanocytes and melanoma biology

  2013cites this paper
• Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene

  2013cites this paper
• Change is in the air: the hypoxic induction of phenotype switching in melanoma.

  2013cites this paper
• HIF1α and HIF2α independently activate SRC to promote melanoma metastases.

  2013influential citation
• HIF1α and HIF2α independently activate SRC to promote melanoma invasion and metastasis

  2013influential citation
• Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas.

  2013cites this paper
• HIF-1alpha in lung carcinoma: Histopathological evidence of hypoxia targets in patient biopsies

  2013cites this paper
• Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

  2013cites this paper
• Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

  2013cites this paper
• [Role of tumor microenvironment in the formation and progression of skin melanoma].

  2013cites this paper
• Loss of microRNA-205 expression is associated with melanoma progression

  2012cites this paper
• miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.

  2012cites this paper
• Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.

  2012cites this paper
• Hypoxia‐induced response of cell cycle and apoptosis regulators in melanoma

  2012cites this paper
• Identification of the Hypoxia-inducible Factor 2α Nuclear Interactome in Melanoma Cells Reveals Master Proteins Involved in Melanoma Development*

  2012cites this paper
• Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation

  2012cites this paper